Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at Hôpital Foch in Suresnes. The protocol has been approved within the United States, United Kingdom, Switzerland, France, and Germany and will have over a dozen sites participating. The principal objective of this study is to evaluate the immunologically mediated anticancer effects of IP-001 injected following the use of thermal ablation in patients with advanced solid tumors. This multinational clinical trial sponsored by Immunophotonics is currently enrolling patients for treatment of colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma.
Immunophotonics is grateful for the opportunity to gain valuable insights from the talented individuals at our trial sites in France.
Read More: (Official Press Release)